Skip to main
RNXT

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx Inc demonstrated a notable increase in revenue for Q2, reaching $422,000, which is a substantial rise from $197,000 in Q1. The company is positioned for significant revenue growth, with projections estimating revenues of $1.3 million in 2025 and $4.5 million in 2026. Given its innovative Trans-Arterial Micro-Perfusion therapy platform designed for targeted cancer treatments, RenovoRx’s financial trajectory suggests a promising outlook as it addresses high unmet medical needs in oncology.

Bears say

RenovoRx Inc is operating in a challenging medical landscape, particularly with pancreatic cancer, which has an alarmingly low five-year overall survival rate of only 12%. The company reported a modest revenue of $0.3 to $0.4 million against a net loss of $2.9 million, consistently achieving an EPS of $(0.08), which aligns with the lower end of consensus estimates. Despite potential growth prospects, the financial metrics reveal a concerning picture of sustainability, with net losses and low revenue casting a negative outlook on the company’s future performance.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.